☰

Vani Vannappagari, Ph.D. - Publications

Affiliations: 
University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
glioblastoma
Tree Info Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Mocroft A, Pelchen-Matthews A, Hoy J, Llibre JM, Neesgaard B, Jaschinski N, Domingo P, Rasmussen LD, Günthard HF, Surial B, Öllinger A, Knappik M, De Wit S, Wit F, Mussini C, ... ... Vannappagari V, et al. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes. Aids (London, England). PMID 38079588 DOI: 10.1097/QAD.0000000000003798  0.401
2023 Sension MG, Brunet L, Hsu RK, Fusco JS, Cochran Q, Uranaka C, Sridhar G, Vannappagari V, Van Wyk J, McCurdy L, Wohlfeiler MB, Fusco GP. Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort. Infectious Diseases and Therapy. PMID 37966701 DOI: 10.1007/s40121-023-00890-2  0.334
2023 Álvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem VN, Günthard HF, Zangerle R, Smith C, Castagna A, D Arminio Monforte A, Wit F, Stecher M, Lehman C, Mussini C, ... ... Vannappagari V, et al. Plasma HIV-1 RNA and CD4+ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens: A prospective RESPOND cohort study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 37052343 DOI: 10.1093/cid/ciad219  0.399
2023 Hsu RK, Fusco JS, Henegar CE, Vannappagari V, Clark A, Brunet L, Lackey PC, Pierone G, Fusco GP. Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes. Bmc Infectious Diseases. 23: 91. PMID 36782125 DOI: 10.1186/s12879-023-08038-w  0.407
2022 Patel P, Ford SL, Baker M, Meyer C, Garside L, D'Amico R, Van Solingen-Ristea R, Crauwels H, Polli JW, Seal C, Yagüe Muñoz I, Thiagarajah S, Birmingham E, Spreen WR, Baugh B, ... ... Vannappagari V, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. Hiv Medicine. PMID 36411596 DOI: 10.1111/hiv.13439  0.443
2021 Mounzer KC, Fusco JS, Hsu RK, Brunet L, Vannappagari V, Frost KR, Shaefer MS, Rinehart A, Rawlings K, Fusco GP. Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort. Aids Patient Care and Stds. PMID 34609897 DOI: 10.1089/apc.2021.0064  0.434
2021 Mounzer K, Brunet L, Hsu R, Fusco JS, Vannappagari V, Henegar CE, van Wyk J, Crawford M, Lo J, Fusco GP. Changes in BMI associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States. Aids Research and Human Retroviruses. PMID 34002626 DOI: 10.1089/AID.2020.0287  0.35
2020 Greenberg L, Ryom L, Neesgaard B, Wandeler G, Staub T, Gisinger M, Skoll M, Günthard HF, Scherrer A, Mussini C, Smith C, Johnson M, De Wit S, Necsoi C, Pradier C, ... ... Vannappagari V, et al. Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33354721 DOI: 10.1093/cid/ciaa1878  0.362
2020 Ruderman SA, Crane HM, Nance RM, Whitney BM, Harding BN, Mayer KH, Moore RD, Eron JJ, Geng E, Mathews WC, Willig AL, Burkholder GA, Lindström S, Wood BR, Collier AC, ... Vannappagari V, et al. Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 33148997 DOI: 10.1097/QAI.0000000000002556  0.354
2020 Hsu R, Brunet L, Fusco JS, Mounzer K, Vannappagari V, Henegar CE, Van Wyk J, Curtis L, Lo J, Fusco GP. Incident Type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs. Aids (London, England). PMID 33048874 DOI: 10.1097/QAD.0000000000002718  0.309
2020 Albano J, Scheuerle A, Beckerman K, Mofenson L, Vannappagari V. The Antiretroviral Pregnancy Registry: 30 Years of Monitoring for Congenital Anomalies [OP04-6D] Obstetrics & Gynecology. 135. DOI: 10.1097/01.Aog.0000662960.32653.80  0.323
2019 Pierone G, Henegar C, Fusco J, Vannappagari V, Aboud M, Ragone L, Fusco G. Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA Observational Database. Journal of the International Aids Society. 22: e25418. PMID 31802641 DOI: 10.1002/Jia2.25418  0.334
2019 Fusco J, Henegar C, Quinlivan EB, Vannappagari V, Aboud M, Smith K, Fusco G. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort. Current Hiv Research. PMID 31560291 DOI: 10.2174/1570162X17666190927161537  0.379
2019 Nance RM, Vannappagari V, Smith K, Calingaert B, Johannes C, Saltus C, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mathews WC, Mugavero MJ, et al. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 31107299 DOI: 10.1097/QAI.0000000000002075  0.35
2019 Vannappagari V, Thorne C. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 30939532 DOI: 10.1097/Qai.0000000000002035  0.352
2018 Hsu R, Fusco J, Henegar C, Mounzer K, Wohlfeiler M, Vannappagari V, Aboud M, Curtis L, Fusco G. Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database. Therapeutic Advances in Drug Safety. 9: 675-686. PMID 30546862 DOI: 10.1177/2042098618798350  0.442
2017 Bratton E, Vannappagari V, Kobayashi MG. Prevalence of and risk for gastrointestinal bleeding and peptic ulcerative disorders in a cohort of HIV patients from a U.S. healthcare claims database. Plos One. 12: e0180612. PMID 28666006 DOI: 10.1371/Journal.Pone.0180612  0.439
2016 Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco J, Quercia R, Aboud M, Curtis L. Psychiatric Symptoms in Patients Receiving Dolutegravir. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 27984559 DOI: 10.1097/Qai.0000000000001269  0.35
2015 Vannappagari V, Albano JD, Koram N, Tilson H, Scheuerle AE, Napier MD. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 197: 6-10. PMID 26687320 DOI: 10.1016/J.Ejogrb.2015.11.015  0.334
2015 Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry. Bjog : An International Journal of Obstetrics and Gynaecology. PMID 26269220 DOI: 10.1111/1471-0528.13542  0.402
2015 Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry. Journal of Acquired Immune Deficiency Syndromes (1999). 68: 359-64. PMID 25469525 DOI: 10.1097/Qai.0000000000000465  0.378
2011 Vannappagari V, Nkhoma ET, Atashili J, Laurent SS, Zhao H. Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy. Platelets. 22: 611-8. PMID 21612330 DOI: 10.3109/09537104.2011.582526  0.413
Show low-probability matches.